TITLE

HHS Ordering 20 Million Doses Of Imvamune

PUB. DATE
April 2007
SOURCE
Bioworld Week;4/23/2007, Vol. 15 Issue 17, p3
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the planned acquisition of 20 million doses of Imvamune, a third-generation smallpox vaccine from Kvisgard, Denmark-based Bavarian Nordic AS by the U.S. Department of Health and Human Services, for its strategic national stockpile in Kvisgard, Denmark. The move which is the first potential contract award under the U.S. government's RFP-3 includes an option for the company to provide up to 60 million additional doses, the company said..
ACCESSION #
25089967

 

Related Articles

  • Acambis and Bavarian Nordic Vie for Smallpox Vaccine Contract. Bush, Laura // Pharmaceutical Technology;Sep2005, Vol. 29 Issue 9, p24 

    Reports on the issuance of a request for proposals by the U.S. Department of Health and Human Services to acquire the doses of modified vaccinia Ankara (MVA) vaccine, a highly attenuated live smallpox vaccine. Competition between pharmaceutical firms Acambis PLC and Bavarian Nordic AS for the...

  • Bavarian's Smallpox Vaccine Pact Worth Up To $1.6 Billion. Sheridan, Cormac // BioWorld International;6/6/2007, Vol. 12 Issue 23, p1 

    The article reports on the contract won by Bavarian Nordic A/S to supply a stockpile of next-generation safe smallpox vaccines to the U.S. Department of Health and Human Services. The pharmaceutical company is expected to earn a total of $1.6 billion from the contract. The vaccine produced by...

  • Danish Biopharma Company Secures $500-Million U.S. Contract. Scott, Alex // Chemical Week;6/20/2007, Vol. 169 Issue 21, p31 

    The article highlights the announcement of the U.S. Department of Health and Human Services (HHS) that it had agreed to contract out the manufacture of 20 million doses of smallpox vaccine to biopharmaceutical company Bavarian Nordic for $500 million. The value of the groundbreaking deal could...

  • HHS Ordering 20 Million Doses Of Bavarian Nordic's Imvamune. Boggs, Jennifer // BioWorld Today;4/17/2007, Vol. 18 Issue 74, p1 

    The article reports on the plan of the U.S. Department of Health and Human Services to buy 20 million doses of the Imvamune vaccine from Bavarian Nordic A/S. It might be the first contract award under the U.S. RFP-3, a request for proposals for modified vaccinia ankara (MVA)-based vaccine for...

  • Bavarian Nordic: HHS contract boosts smallpox vaccine franchise.  // PharmaWatch: Monthly Review;Jun2007, Vol. 6 Issue 6, p23 

    The article reports on the U.S. government supply contract earned by Bavarian Nordic for its smallpox vaccine Imvamune. It is stated that the U.S. department of Health and Human Services has informed Bavarian Nordic of its plan to purchase 20 million doses of Imvamune under the BioShield...

  • OTHER NEWS TO NOTE.  // BioWorld Today;8/26/2009, Vol. 20 Issue 164, p5 

    This section offers news briefs on the pharmaceutical industry as of August 2009. Bavarian Nordic AS of Denmark is in negotiation with the government of the U.S. to develop a freeze-dried version of its small pox vaccine Imvamune. Cellceutix Corp. of Massachusetts has acquired rights to the...

  • Bavarian Nordic Rises On First Vaccine Approval. Sheridan, Cormac // BioWorld International;8/14/2013, Vol. 18 Issue 33, p5 

    The article reports on the 6.6% increase in pharmaceutical company Bavarian Nordic A/S shares. It notes that this increase resulted from European Commission's approval of Bavarian Nordic's third-generation smallpox vaccine Imnavex which is based on a modified vaccinia Ankara (MVA) vector. The...

  • Bavarian Nordic shares rise on collaboration deal with GSK.  // PharmaWatch: Biotechnology;September 2004, Vol. 3 Issue 9, p18 

    Reports on the collaboration between Bavarian Nordic and GlaxoSmithKline on the production and marketing of Bavarian's smallpox vaccine Imvamue. Terms of the collaborative contract; Responsibility of Bavarian for development and production of Imvamune to the U.S. government under the National...

  • Bavarian Nordic loses smallpox vaccine case to Acambis.  // PharmaWatch: Biotechnology;Jul2007, Vol. 6 Issue 7, p19 

    The article reports on the dismissal of Bavarian Nordic AS's claims against Acambis PLC by the Federal District Court of the District of Delaware. The court has dismissed the Danish company's claims against British biotechnology firm of unfair competition relating to virus material used to...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics